Previously, IHC-based MSI testing for MLH1 and MSH2 provided a sensitive (92.3%) and an extremely specific (100%) method for screening defects in DNA mismatch repair in CRC patients [37]. This evidence concerns the gene MLH1 and colorectal carcinoma.